Deciphera Pharmaceuticals Inc (DCPH)
25.46
+0.02
(+0.06%)
USD |
NASDAQ |
May 17, 16:00
25.46
0.00 (0.00%)
After-Hours: 20:00
Deciphera Pharmaceuticals Gross Profit Margin (Quarterly): 95.36% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 95.36% |
| December 31, 2023 | 96.30% |
| September 30, 2023 | 97.03% |
| June 30, 2023 | 99.55% |
| March 31, 2023 | 98.54% |
| December 31, 2022 | 91.07% |
| September 30, 2022 | 90.70% |
| June 30, 2022 | 94.46% |
| Date | Value |
|---|---|
| March 31, 2022 | 98.69% |
| December 31, 2021 | 97.86% |
| September 30, 2021 | 96.05% |
| June 30, 2021 | 94.59% |
| March 31, 2021 | 99.12% |
| December 31, 2020 | 99.35% |
| September 30, 2020 | 99.42% |
| June 30, 2020 | 99.89% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
90.70%
Minimum
Sep 2022
99.89%
Maximum
Jun 2020
96.75%
Average
97.45%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 75.29% |
| Dynavax Technologies Corp | 78.41% |
| Gilead Sciences Inc | 76.79% |
| Esperion Therapeutics Inc | 92.69% |
| SINTX Technologies Inc | 23.67% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -50.29% |
| Return on Assets | -38.85% |
| Return on Invested Capital | -50.29% |
| Profit Margin (Quarterly) | -100.2% |
| Operating Margin (Quarterly) | -108.6% |
| Return on Net Operating Assets | -200.2% |